Masimo guarantees its Masimo SET pulse oximetry
will outperform any other commercially available technology in a
hospital evaluation or it will pay up to $500,000
Irvine, California February 7, 2007 - Masimo, the inventor of Pulse
CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry,
today announced that it is expanding its $500,000 performance guarantee
to include all other commercially available pulse oximetry
technologies. If, after a side-by-side hospital evaluation, Masimo SET
does not outperform any other commercially available pulse oximetry
technology under the most challenging conditions of motion and low
perfusion, Masimo will pay up to $500,000 towards the purchase of that
pulse oximetry. This offer is available only to hospitals whose goal is
to upgrade their pulse oximetry hospital-wide. Important details,
conditions and qualifications for the guarantee are available on
Masimo's web page: http://www.masimo.com.
Masimo SET is the most accurate and reliable pulse oximetry
technology in the world under conditions of motion and low perfusion,
clinically proven in more than 100 independent and objective studies to
provide the most trustworthy SpO2 readings even under the
most difficult clinical conditions. These studies prove Masimo
SET delivers improvements in outcomes, safety and efficiency while
decreasing costs. Because of this, Masimo SET is considered the "gold
standard" pulse oximetry technology.
"We are hopeful that decision makers within hospitals see this
guarantee as a 'can't lose' offer," stated Joe E. Kiani, Founder and
CEO of Masimo. "If the evaluation proves that their level of care can
be improved with Masimo SET, not only will they benefit from improved
patient outcomes and safety, but in most cases, the conversion can be
completed with no capital outlay and no increase in annual operating
costs. If the evaluation proves that Masimo is not the best performing,
the hospital will receive $500,000 towards the purchase of another
technology that can deliver similar patient care benefits."
Mr. Kiani continued: "We have converted hundreds of leading hospitals, including nearly two thirds of hospitals on the U.S. News and World Reports
Honor Roll. The national drive to improve patient care and safety and
reduce medical errors has been a primary driver for many of these
hospitals' decision to evaluate and convert to Masimo SET technology.
We are grateful that our products can play a role in this noble
endeavor."
About Masimo
Masimo develops innovative
monitoring technologies that significantly improve patient care-helping
solve "unsolvable" problems. In 1995, the company debuted Read-Through
Motion and Low Perfusion pulse oximetry, known as SET and with it
virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent
clinical studies have confirmed that Masimo SET technology allows
clinicians to accurately monitor blood oxygen saturation in critical
care situations-establishing the technology as the "gold standard"
pulse oximetry and substantially contributing to improved patient
outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse
CO-Oximetry, which, for the first time, noninvasively monitors the
level of carbon monoxide and methemoglobin in the blood, allowing early
detection and treatment of potentially life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient Outcomes
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications." Additional information about Masimo and its products
may be found at www.masimo.com
Contact:
Tom McCall
Masimo Corporation
949-297-7075
Masimo, SET, Signal Extraction Technology,
Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications are registered trademarks of Masimo Corp. Rainbow, SpCO,
SpMet, SpHb and Pulse CO-Oximeter are trademarks of Masimo Corp.